Enoxaparin Versus Unfractionated Heparin in PCI

Phase 4CompletedNCT00439855

Triemli Hospital2,100 enrolled

Overview

Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

2,100

Conditions

Coronary Artery Disease

Interventions

Enoxaparin i.v.DRUG

unfractionated heparinDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * PCI for stable ischemia or ACS Exclusion Criteria: * Cardiogenic shock, * Pretreatment with study drugs, * Lack of informed consent

Locations (1)

Division of Cardiology Triemli Hospital Zurich

Zurich, Switzerland

Outcomes

Primary Outcomes

Quadruple endpoint: death, MI, urgent TVR, major bleeding

Secondary Outcomes

major bleeding, minor bleeding, thrombocytopenia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.